Navigation Links
Angioslide Announces FDA 510(K) Clearance of PROTEUS(TM) Below The Knee Device
Date:5/2/2012

CAESAREA, Israel, May 2, 2012 /PRNewswire/ --

Angioslide Ltd. a provider of Embolic Capture Angioplasty solutions, today announced that it has received FDA 510(K) clearance for its new 3X100mm PROTEUS device for treating Peripheral Artery Disease in below the knee (BTK) vasculature.  The new 3/100mm device accommodates 0.014" guide-wires, which significantly broadens the potential use of PROTEUS technology.  

Angioslide's proprietary technology combines the functionality of a balloon angioplasty device with the addition of built-in embolic capture. PROTEUS is a competitive PTA (Percutaneous Transluminal Angioplasty) balloon with features similar to leading PTA balloons (deflation time, pushability, crossing profile). Then, during deflation, the PROTEUS captures and retrieves potentially harmful embolic material.  The capture of embolic material is enabled by the inward folding of the balloon, which creates a low pressure cavity. The negative pressure in this cavity generates an aspiration effect, pulling embolic material into the cavity.  When retrieved through the sheath, PROTEUS removes the captured material from the body.

Below-the-Knee (BTK) interventions are often characterized by patients with long and diffuse lesions, diabetic foot ulcers and/or Critical Limbs Ischemia (CLI).  PROTEUS 3X100 offers physicians, for the first time, the ability to capture and remove embolic material with a single device during these challenging interventions.    

"Introduction of the new dedicated, BTK, low-profile 0.014" PROTEUS platform, supports Angioslide continuing commitment to improve procedure outcomes. Distal embolic complications in this compromised group of patients further risk blood flow to the foot. PROTEUS will become a necessary device in the "tool-box" of physicians practicing "endovascular-first" approach," said Lihu Avitov, Angioslide CEO.  

About Angioslide

Founded in 2005, Angioslide is a privately held medical device company that developed a unique Embolic Capture Angioplasty solution, PROTEUS™, which provides a combination of PTA balloon and embolic capture. The PROTEUS™ device addresses an unmet need for an easy-to-use, efficient and cost-effective embolic particle capture solution for the peripheral vascular disease market. It is the first device of its kind to receive FDA clearance for use in lower limbs. The device has also received European CE Mark approval for lower limb use and is being marketed in selected regions in Europe. Angioslide headquarters are located in Caesarea, Israel, and Denver Colorado.  For more information visit our website at http://www.angioslide.com

Contact:
Shira Doron
Marketing Director
Mobile: +972-54-9011134
shirad@angioslide.com

 



'/>"/>
SOURCE Angioslide Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Angioslide Announces the European Launch of New 300 mm Long Device Allowing Treatment of Entire Superficial Femoral Artery(SFA) with One Device
2. Angioslide Commercializes in the U.S. First Device to Combine Balloon Angioplasty and Embolic Capture
3. Hill-Rom Announces Third Quarter 2012 Dividend
4. Trovagene Announces Plans to Develop Proprietary Test for High Risk HPV Carrier Screening from Urine
5. Medical Guardian Announces Social Media Partnership with Senior Citizen Charity
6. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
7. ConvaTec Announces Acquisition of AbViser Medical, LLC
8. Cardica Announces Fiscal 2012 Third Quarter Financial Results
9. Arena Pharmaceuticals Announces First Quarter 2012 Financial Results and Recent Developments
10. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
11. Acella Pharmaceuticals Announces a New Addition to the Commercial Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... N.C. , Feb. 24, 2017 ... exploring ways to increase their self-service capabilities to ... Care Providers (HCPs). New research from ... pharma organizations have developed self-service website portals where ... This is just one of many findings to ...
(Date:2/24/2017)... 24 février 2017 ITL Limited, ( ASX : ITD ), ... ravie d,annoncer les excellents résultats semestriels clos le 31 ... Une présentation complète « Résultats et mise à jour sur ... . Faits marquants ... 1,04 million $ ; en hausse de 104 %) ...
(Date:2/24/2017)... Medivir AB (Nasdaq Stockholm: MVIR) ... Board of Directors that will be submitted to the ... representatives of the company,s three largest shareholders at the ... accepted a seat on the Nomination Committee, and the ... Nomination Committee was as follows:  ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 2017 , ... Houston dentist , Dr. Behzad Nazari, ... Center. Currently, patients can get single dental implants for $3,599 and All On ... more about these offers by contacting Antoine Dental Center. Both of these options ...
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. ... has officially announced the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., ... (LUCOM), beginning April 10. Dr. Bell comes to Liberty from the Ohio ...
(Date:2/24/2017)... ... ... Healthcare Associates of McKinney announced today that they have moved one ... 121, Suite 210, McKinney, Texas 75070. It is in the heart of the ... has grown, the need for more space has been paramount. This beautiful new ...
(Date:2/24/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has published a ... an astounding statement when he says that the entire Bible was written for the ... times so plainly that anyone should be able to see the time period. He ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... specializes in thought leadership , media relations, social media, content marketing and ... will be powered through Act-On, an intuitive marketing automation platform. , Rosica will ...
Breaking Medicine News(10 mins):